Effect of Low-Level Laser Therapy on Salivary Toll Like Receptor- 4 Concentration of Periodontitis Patients: a Relation to Periodontal Inflammaging

November 5, 2024 updated by: Rawda Saleh Saad Alashmawy
Effect of Low-Level Laser Therapy on Salivary Toll Like Receptor- 4 Concentration of Periodontitis Patients: A Relation to Periodontal Inflammaging

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Detailed Description

Effect of Low-Level Laser Therapy on Salivary Toll Like Receptor- 4 Concentration of Periodontitis Patients: A Relation to Periodontal Inflammaging

Study Type

Interventional

Enrollment (Actual)

40

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Egypt
      • Giza, Egypt, 3220001
        • Misr University for Science and Technology

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  1. Male or Female
  2. Aged below 40 or above 60.
  3. Have at least 16 natural teeth excluding wisdom.
  4. Provide informed consent and willingness to cooperate with study protocol.

  5. Periodontitis stage II patients (23):

    • CAL from 3-4 mm.
    • Radiographic bone loss (15% to 33%).
    • No tooth loss due to periodontitis.
    • Maximum probing depth ≤ 5 mm, mostly horizontal bone loss

Exclusion Criteria:

  • 1- Patients with any smoking habits 2- History of antibiotics in the previous three months. 3- Pregnant or lactating female. 4- Treatment with any systemic drug. 5- History of systemic disease. 6- Patients who received periodontal treatment in the last 6 months

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Quadruple

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: conventional scaling and debridement young age patient
Procedure: conventional scaling and debridement
conventional scaling and debridement
Experimental: conventional scaling and debridement old age patient
Procedure: conventional scaling and debridement
conventional scaling and debridement
Experimental: diode laser as adjunctive to scaling and debridement young age patient
Radiation: Diode laser as adjunctive to conventional scaling and debridement
Diode laser as adjunctive to conventional scaling and debridement
Experimental: diode laser as adjunctive to scaling and debridement old age patient
Radiation: Diode laser as adjunctive to conventional scaling and debridement
Diode laser as adjunctive to conventional scaling and debridement

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Time Frame
Clinical attachment loss
Time Frame: Base line , follow up after 1 month , second follow up after 6 months
Base line , follow up after 1 month , second follow up after 6 months
Gingival index
Time Frame: base line, follow up after 1 month, second follow up after 6 months
base line, follow up after 1 month, second follow up after 6 months
Toll like receptor - 4
Time Frame: base line, follow up after 1 month, second follow up after 6 months
base line, follow up after 1 month, second follow up after 6 months

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Rawda Saleh Saad Alashmawy

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

July 12, 2023

Primary Completion (Actual)

March 12, 2024

Study Completion (Actual)

October 12, 2024

Study Registration Dates

First Submitted

November 5, 2024

First Submitted That Met QC Criteria

November 5, 2024

First Posted (Estimated)

November 7, 2024

Study Record Updates

Last Update Posted (Estimated)

November 7, 2024

Last Update Submitted That Met QC Criteria

November 5, 2024

Last Verified

November 1, 2024

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • 2022\0083

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

UNDECIDED

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

Yes

product manufactured in and exported from the U.S.

Yes

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe